CCR5 and neoplasm: Following Balistreri et al. [129] that observed a very low prevalence of prostate cancer in men with CCR5 delta 32 mutations, which also confers HIV resistance, we have used mice lacking CCR5 to uncover the contribution of CCR5 to the cancer resistance and found that in these mice accumulation of MDSC at the tumor site is inadequate [130].